The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GALT | +83.1% | +101.55% | +15.03% | -57% |
| S&P | +12.65% | +91.73% | +13.89% | +653% |
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Find out why these three biotech stocks could be huge winners.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 77.8% |
| Market Cap | $133.55M | -4.9% |
| Market Cap / Employee | $8.90M | 0.0% |
| Employees | 15 | 7.1% |
| Net Income | -$7.52M | 39.2% |
| EBITDA | -$4.62M | 59.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $13.77M | -46.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $120.46M | 28.9% |
| Short Term Debt | $0.05M | 18.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -186.51% | -1.0% |
| Return On Invested Capital | -158.30% | 58.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.60M | 20.8% |
| Operating Free Cash Flow | -$6.60M | 20.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.03 | -0.85 | -0.73 | -1.17 | -39.11% |
| Price to Tangible Book Value | -2.03 | -0.85 | -0.73 | -1.17 | -39.11% |
| Enterprise Value to EBITDA | -27.71 | -14.03 | -22.81 | -52.53 | 181.20% |
| Total Debt | $104.59M | $106.25M | $107.99M | $120.51M | 28.94% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
